Company Edwards Lifesciences Corporation
Equities
EW
US28176E1082
Advanced Medical Equipment & Technology
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 83.10 USD | -0.88% |
|
-2.04% | -2.52% |
Business description: Edwards Lifesciences Corporation
- heart valves and surgery products (75.5%);
- hemodynamic monitoring systems (6.5%);
- other (18%): balloon catheters, artificial implants, etc.
Net sales are distributed geographically as follows: the United States (58.9%), Europe (24.3%), Japan (6.3%) and others (10.5%).
Number of employees: 15,800
Sales by Activity: Edwards Lifesciences Corporation
| Fiscal Period: December | 2020 (USD) | 2021 (USD) | 2022 (USD) | 2023 (USD) | 2024 (USD) |
|---|---|---|---|---|---|
Medical Products | 4.39B | 5.23B | 5.38B | 6B | 5.44B |
Geographical breakdown of sales: Edwards Lifesciences Corporation
| Fiscal Period: December | 2020 (USD) | 2021 (USD) | 2022 (USD) | 2023 (USD) | 2024 (USD) |
|---|---|---|---|---|---|
United States | 2.52B | 2.96B | 3.13B | 3.51B | 3.21B |
Europe | 974M | 1.19B | 1.17B | 1.33B | 1.32B |
Rest of World | 436M | 550M | 601M | 709M | 572M |
Japan | 460M | 529M | 474M | 452M | 340M |
Executive Committee: Edwards Lifesciences Corporation
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 58 | 11/05/2023 | |
Scott Ullem
DFI | Director of Finance/CFO | 59 | 01/01/2014 |
Todd Brinton
CTO | Chief Tech/Sci/R&D Officer | - | 01/02/2019 |
Mark D. Peterson
LAW | General Counsel | 63 | - |
Andrew Dahl
AUD | Comptroller/Controller/Auditor | 49 | 01/02/2024 |
Composition of the Board of Directors: Edwards Lifesciences Corporation
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 69 | 07/05/2024 | |
Kieran Gallahue
BRD | Director/Board Member | 62 | 10/02/2015 |
| Director/Board Member | 58 | 11/05/2023 | |
Steven Loranger
BRD | Director/Board Member | 74 | 16/03/2016 |
Leslie Heisz
BRD | Director/Board Member | 65 | 05/07/2016 |
Ramona Sequeira
BRD | Director/Board Member | 60 | 07/05/2020 |
Paul LaViolette
BRD | Director/Board Member | 68 | 13/07/2020 |
David Feinberg
BRD | Director/Board Member | 63 | 10/07/2024 |
Leslie Davis
BRD | Director/Board Member | 67 | 07/05/2024 |
Holdings: Edwards Lifesciences Corporation
| Name | Equities | % | Valuation |
|---|---|---|---|
| 3,540,287 | 9% | 7 M $ |
Company details: Edwards Lifesciences Corporation
Group companies: Edwards Lifesciences Corporation
| Name | Category and Sector |
|---|---|
Edwards Lifesciences (India) Pvt Ltd.
 Edwards Lifesciences (India) Pvt Ltd. Designs, develops, manufactures and markets products to treat late-stage cardiovascular disease | |
Edwards Lifesciences (India) Pvt Ltd.
Edwards Lifesciences (India) Pvt Ltd. Designs, develops, manufactures and markets products to treat late-stage cardiovascular disease | |
Edwards Lifesciences World Trade Corp.
 Edwards Lifesciences World Trade Corp. Manufactures medical devices for cardiovascular diseases | |
Edwards Lifesciences World Trade Corp.
Edwards Lifesciences World Trade Corp. Manufactures medical devices for cardiovascular diseases | |
Edwards Lifesciences Technology SARL |
Other Advanced Medical Equipment & Technology
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.88% | -2.04% | +16.98% | +6.12% | 48.22B | |
| +2.43% | +0.76% | +11.64% | +6.51% | 234B | |
| -2.68% | -7.68% | +1.46% | +111.19% | 194B | |
| +1.01% | +1.01% | +0.14% | -13.04% | 168B | |
| -0.42% | -4.98% | -2.00% | +101.46% | 139B | |
| -0.28% | +1.01% | -8.77% | -6.41% | 61.18B | |
| -0.27% | -1.28% | +1.74% | -7.01% | 41.37B | |
| +0.63% | -0.54% | +1.39% | +30.35% | 38.86B | |
| +1.90% | +4.55% | +13.41% | +18.99% | 37.8B | |
| -0.22% | +3.43% | -11.97% | -37.20% | 36.03B | |
| Average | +0.13% | -0.56% | +2.40% | +21.09% | 99.8B | |
| Weighted average by Cap. | +0.19% | -1.63% | +3.24% | +35.22% |
Sector
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- EW Stock
- Company Edwards Lifesciences Corporation
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition